In this issue:
Early life exposure to antibiotics increases the risk for AD
Association of AD severity with learning disability in children
Does AD impact educational attainment?
Moderate-to-severe AD in adults has a high economic and psychosocial burden
Real-world effectiveness of dupilumab for moderate-to-severe AD
Baricitinib safety profile in adults confirmed by integrated analysis of eight clinical trials
Dupilumab therapy safe and effective for elderly patients
Real-world experience and laboratory monitoring of dupilumab
Efficacy and safety of methotrexate in moderate-to-severe AD
Weight reduction significantly improves AD severity
Please login below to download this issue (PDF)